{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:23:36Z","timestamp":1779222216160,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40257-020-00523-1","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T18:03:32Z","timestamp":1590689012000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Topical Minocycline Foam 4%: A Review in Acne Vulgaris"],"prefix":"10.1007","volume":"21","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"523_CR1","doi-asserted-by":"crossref","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373 e33.","DOI":"10.1016\/j.jaad.2015.12.037"},{"issue":"9813","key":"523_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","volume":"379","author":"HC Williams","year":"2012","unstructured":"Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361\u201372.","journal-title":"Lancet."},{"issue":"2","key":"523_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11136-019-02318-2","volume":"29","author":"GF Cengiz","year":"2020","unstructured":"Cengiz GF, Gurel G. Difficulties in emotion regulation and quality of life in patients with acne. Qual Life Res. 2020;29(2):431\u20138.","journal-title":"Qual Life Res."},{"issue":"Suppl 5","key":"523_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","volume":"60","author":"D Thiboutot","year":"2009","unstructured":"Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(Suppl 5):S1\u201350.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"523_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/jdv.12298","volume":"28","author":"CC Zouboulis","year":"2014","unstructured":"Zouboulis CC, Jourdan E, Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. J Eur Acad Dermatol Venereol. 2014;28(5):527\u201332.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"523_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-014-0099-z","volume":"15","author":"S Das","year":"2014","unstructured":"Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15(6):479\u201388.","journal-title":"Am J Clin Dermatol."},{"issue":"4","key":"523_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40257-017-0267-z","volume":"18","author":"A Bienenfeld","year":"2017","unstructured":"Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18(4):469\u201390.","journal-title":"Am J Clin Dermatol."},{"issue":"3","key":"523_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40257-018-00417-3","volume":"20","author":"H Xu","year":"2019","unstructured":"Xu H, Li H. Acne, the skin microbiome, and antibiotic treatment. Am J Clin Dermatol. 2019;20(3):335\u201344.","journal-title":"Am J Clin Dermatol."},{"issue":"10","key":"523_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3855\/jidc.6862","volume":"10","author":"I Biswal","year":"2016","unstructured":"Biswal I, Gaind R, Kumar N, et al. In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris. J Infect Dev Ctries. 2016;10(10):1140\u20135.","journal-title":"J Infect Dev Ctries."},{"key":"523_CR10","unstructured":"Foamix Pharmaceuticals Ltd. AMZEEQ\u2122 (minocycline) topical foam: US prescribing information. 2019. https:\/\/www.fda.gov\/. Accessed 16 Apr 2020."},{"issue":"4","key":"523_CR11","first-page":"14","volume":"13","author":"L Kircik","year":"2020","unstructured":"Kircik L, Del Rosso JQ, Weiss JS, et al. Formulation and profile of FMX101 4% minocycline topical foam for the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2020;13(4):14\u201321.","journal-title":"J Clin Aesthet Dermatol."},{"key":"523_CR12","doi-asserted-by":"publisher","first-page":"102169","DOI":"10.1016\/j.anaerobe.2020.102169","volume":"62","author":"J Sutcliffe","year":"2020","unstructured":"Sutcliffe J, McLaughlin R, Webster G, et al. Susceptibility of Cutibacterium acnes to topical minocycline foam. Anaerobe. 2020;62:102169.","journal-title":"Anaerobe."},{"issue":"10","key":"523_CR13","first-page":"1022","volume":"16","author":"TM Jones","year":"2017","unstructured":"Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol. 2017;16(10):1022\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"5","key":"523_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/pde.13992","volume":"36","author":"L Eichenfield","year":"2019","unstructured":"Eichenfield L, Stein Gold L, Silverberg N, et al. Clinical safety and pharmacokinetics of FMX101 4% topical minocycline foam in pediatric patients for the treatment of moderate-to-severe acne vulgaris [poster]. Pediatr Dermatol. 2019;36(5):767\u201395.","journal-title":"Pediatr Dermatol."},{"issue":"4","key":"523_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaad.2019.05.078","volume":"82","author":"TJ Raoof","year":"2020","unstructured":"Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2020;82(4):832\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"523_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2018.08.020","volume":"80","author":"L Stein Gold","year":"2019","unstructured":"Stein Gold L, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80(1):168\u201377.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"523_CR17","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaad.2015.09.065","volume":"74","author":"A Shemer","year":"2016","unstructured":"Shemer A, Shiri J, Mashiah J, et al. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016;74(6):1251\u20132.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"523_CR18","first-page":"16","volume":"12","author":"L Stein Gold","year":"2019","unstructured":"Stein Gold L, Dhawan S, Weiss J, et al. Open-label extension study evaluating long-term safety and efficacy of FMX101 4% minocycline foam for moderate-to-severe acne vulgaris. J Clin Aesthet Dermatol. 2019;12(10):16\u201323.","journal-title":"J Clin Aesthet Dermatol."},{"key":"523_CR19","doi-asserted-by":"crossref","unstructured":"Stein Gold L, Dhawan S, Weiss J, et al. An open-label extension of two phase 3 studies evaluating long-term efficacy of FMX101 4% minocycline foam for the treatment of acne vulgaris [poster]. In: 15th Annual Coastal Dermatology Symposium. 2019.","DOI":"10.25251\/skin.3.supp.1"},{"issue":"1","key":"523_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/1547691X.2019.1610117","volume":"16","author":"J Dosik","year":"2019","unstructured":"Dosik J, Ellman H, Stuart I. Topical minocycline foam 4%: results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation. J Immunotoxicol. 2019;16(1):133\u20139.","journal-title":"J Immunotoxicol."},{"issue":"11","key":"523_CR21","first-page":"740","volume":"95","author":"L Hauk","year":"2017","unstructured":"Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95(11):740\u20131.","journal-title":"Am Fam Physician."},{"key":"523_CR22","unstructured":"Ranbaxy Laboratories Ltd. XIMINO\u2122 (minocycline hydrochloride) extended-release capsules: US prescribing information. 2015. https:\/\/www.fda.gov\/. Accessed 16 Apr 2020."},{"key":"523_CR23","unstructured":"Medicis Pharmaceutical Corporation. SOLODYN\u00ae (minocycline hydrochloride) extended release tablets: US prescribing information. 2013. https:\/\/www.fda.gov\/. Accessed 16 Apr 2020."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00523-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:12:21Z","timestamp":1622160741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00523-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00523-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Paik is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}